Prevalence of Trypanosoma cruzi Infection in Solid Organ Transplant Recipients
Author Information
Author(s): German A. Contreras, George Golovko
Primary Institution: University of Texas Medical Branch at Galveston
Hypothesis
What is the prevalence of Trypanosoma cruzi infection among solid organ transplant recipients in the United States from 2019 to 2023?
Conclusion
The study found a 4.8% prevalence of T. cruzi infection among solid organ transplant recipients, highlighting the need for improved screening protocols.
Supporting Evidence
- The overall prevalence of positive T. cruzi serology in this cohort was 4.8%.
- Lung and heart transplant recipients had the highest prevalence rates.
- Thirteen patients were diagnosed with T. cruzi reactivation within the first year after transplantation.
- All reactivation cases were treated with benznidazole, with no deaths attributed to Chagas disease.
Takeaway
This study shows that some people who get organ transplants in the U.S. might have a bug called T. cruzi, which can make them sick, so doctors need to check for it more often.
Methodology
A retrospective study analyzing data from a large multicenter network to determine the seroprevalence of T. cruzi among solid organ transplant recipients.
Potential Biases
Potential selection bias due to variable data update schedules across participating health care organizations.
Limitations
The study's retrospective design and reliance on de-identified data limit access to detailed patient histories and specific serological test information.
Participant Demographics
The cohort included 60% males, with a median age of 52 years, and a significant number identified as Hispanic.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website